Navigation Links
Spherix to Present at the 13th Annual BIO CEO & Investor Conference
Date:2/8/2011

BETHESDA, Md., Feb. 8, 2011 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its President, Dr. Robert Lodder, will be presenting at the 13th Annual BIO CEO & Investor Conference to be held in New York next week.

Dr. Lodder will deliver the Company's corporate presentation on Tuesday, February 15, 2011, at 8:00 a.m. in the Conrad Suite of the Waldorf Astoria.  Dr. Claire Kruger, Chief Executive Officer, will be accompanying Dr. Lodder.

The BIO CEO & Investor Conference is the largest independent investor conference focused on publicly traded biotechnology companies.  This conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.  The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.

About Spherix

Spherix Incorporated was launched in 1967 as a scientific research company under the name Biospherics Research.  The Company now leverages its scientific and technical expertise and experience through its two subsidiaries – Biospherics Incorporated and Spherix Consulting, Inc.  Biospherics is dedicated to development of D-tagatose and recently completed a Phase 3 clinical trial to study the use of D-tagatose as a treatment for Type 2 diabetes.  Biospherics is actively seeking a pharma partner to continue the diabetes development while exploring D-tagatose as a potential treatment for high triglycerides, a risk factor for atherosclerosis, myocardial infarction, and stroke. Spherix's Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products and industrial chemicals and pesticides.  For more information, please visit www.spherix.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of D-tagatose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop D-tagatose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Announces Closing of Registered Direct Offering of $2.77 Million in Common Stock and Warrants
2. Spherix to Present at Two Upcoming Prominent Finance Conferences
3. Spherix Phase 2 Trial with D-tagatose Determines Minimum Dose for HbA1c and Triglycerides
4. Spherix Signs Research Contract With a Leading Global Contract Research Organization to Investigate Role of D-tagatose in Lowering Triglycerides
5. Spherix to Hold Business Update Conference Call December 9, 2010 at 4:30 p.m. Eastern Time
6. Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants
7. Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes
8. Spherix Announces Second Quarter 2010 Financial Results
9. Spherix Announces the Closing of $6.3 Million Registered Direct Offering
10. Spherix Announces Results of Annual Shareholders Meeting
11. Spherix Incorporated Announces Annual Shareholders Meeting Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... RADNOR, Pa., Feb. 24, 2017  VWR Corporation (NASDAQ: VWR), ... to laboratory and production customers, today reported its financial results ... 2016. Highlights: 4Q16 record ... up 1.0% on an organic basis. ... on an organic basis, while the Americas net sales increased ...
(Date:2/23/2017)... Financial ... data, unaudited)Three Months Ended December 31,Twelve Months Ended December ... $           300$ ... Net Product Revenue 3539(10)%9498(4)%Kuvan Net ... Revenue  756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced ... for two key immunotherapy technologies from the University ... provides a method to monitor a patient for ... PD-L1 and CTLA-4.  The second license extends the ... patient is likely to have an immune-related adverse ...
(Date:2/23/2017)... Feb. 23, 2017  Imanis Life Sciences announced ... of oncolytic vaccinia viruses for virotherapy research. These ... of Genelux,s proprietary, vaccinia virus-based technology platform for ... enter into a partnership with Genelux to offer ... viruses for use in research," said Dr. ...
Breaking Biology Technology:
(Date:2/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the LEERINK Partners 6th Annual Global Healthcare Conference at ... 15, 2017 at 10 a.m. Eastern Time. ... accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will be ... Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:1/30/2017)... FRANCISCO , Jan. 30, 2017   Invitae ... the fastest growing genetic information companies, today announced that ... financial results and provide 2017 guidance on Monday, February ... conference call that day at 4:45 p.m. Eastern / ... Invitae,s management team will briefly review financial results, guidance, ...
Breaking Biology News(10 mins):